Resistell presents spectacular study results

Congratulations to our portfolio company Resistell. The Basel-based start-up announced the successful completion of the pilot phase of its clinical Performance Evaluation Study with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.

Resistell is developing the world’s fastest phenotypic Antibiotic Susceptibility Test (AST) with its groundbreaking nanomotion technology platform.

More information in the press release under the following Link.

More about Resistell

adivo receives EIC Accelerator Grant Overview Our CEO in the German Handelsblatt
Want to learn more about OCCIDENT?